On April 8, 2022, Daniel Menichella tendered his resignation from the Kaleido Biosciences, Inc.'s Board of Directors, and all committees of the Board of Directors on which he served. On April 8, 2022, the employment of each of (i) Daniel Menichella, the Company's principal executive officer and named executive officer, (ii) William Duke, the Company's principal financial and accounting officer and named executive officer, and (iii) Johan van Hykckama Vlieg, a named executive officer, was terminated effective immediately in connection with the Company's cessation of operations.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | 0.00% | 0.00% | +9,900.00% |
2022 | Kaleido Biosciences, Inc.(NasdaqGS:KLDO) dropped from S&P Global BMI Index | CI |
2022 | Kaleido Biosciences, Inc.(NasdaqGS:KLDO) dropped from S&P TMI Index | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+9,900.00% | 4.26K | |
+23.37% | 46.71B | |
+48.83% | 41.8B | |
-0.94% | 41.52B | |
-5.86% | 29.55B | |
+11.29% | 25.78B | |
-20.92% | 19.26B | |
+3.20% | 12.14B | |
-2.67% | 12.08B | |
+30.23% | 11.98B |
- Stock Market
- Equities
- KLDO Stock
- News Kaleido Biosciences, Inc.
- Kaleido Biosciences, Inc. Announces Management Changes